PlainPharmaWatch

CMS Open Payments · Tool

BioMarin Pharmaceutical Inc. vs Catalyst OrthoScience

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Catalyst OrthoScience has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 2,229, versus 639 for the other company. Its single largest recorded recipient represents 0.3% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

BioMarin Pharmaceutical Inc.
HHI 639 · top recipient 0.2%
Ranked #1,207 of 1,838 companies by HHI
Catalyst OrthoScience
HHI 2,229 · top recipient 0.3%
Ranked #710 of 1,838 companies by HHI

Payment Overview

Total Payments
$11.9M
% of Industry
0.1%
Transactions
4,140
Avg per Transaction
$2.9K
Recipients
2,932
Avg per Recipient
$4.0K
Payment Types
7
Top Payment Type
Consulting Fee
Total Payments
$11.8M
% of Industry
0.1%
Transactions
448
Avg per Transaction
$26.4K
Recipients
424
Avg per Recipient
$27.9K
Payment Types
4
Top Payment Type
Royalty or License

Highlighted values indicate the higher figure for each metric.

Total payments compared

BioMarin Pharmaceutical Inc. vs Catalyst OrthoScience - total reported payments in CMS Open Payments PY2024

BioMarin Pharmaceutical Inc.$11.9MCatalyst OrthoScience$11.8M

Payment Types Breakdown

BioMarin Pharmaceutical Inc.

Consulting Fee $1.4M

11.6%

Compensation for Services Other Than Consulting $1.1M

9.5%

Travel and Lodging $277.4K

2.3%

Royalty or License $114.1K

1.0%

Food and Beverage $81.0K

0.7%

Grant $19.9K

0.2%

Catalyst OrthoScience

Royalty or License $406.5K

3.4%

Consulting Fee $172.5K

1.5%

Food and Beverage $28.9K

0.2%

Travel and Lodging $11.1K

0.1%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

BioMarin Pharmaceutical Inc.

  1. 1

    DENNIS SLAMON

    $579,423.26 · 7 txns

  2. 2

    WILLARD DERE

    $423,639.35 · 11 txns

  3. 3

    University Of Alabama Hospital

    $110,000.00 · 1 txns

  4. 4

    STEVEN PIPE

    $71,415.16 · 32 txns

  5. 5

    JULIE HOOVER-FONG

    $61,566.83 · 30 txns

Catalyst OrthoScience

  1. 1

    ZACHARY LEITZE

    $213,231.75 · 8 txns

  2. 2

    THEODORE BLAINE

    $194,148.69 · 10 txns

  3. 3

    NICHOLAS CAPITO

    $28,403.80 · 13 txns

  4. 4

    MIGUEL RAMIREZ

    $24,399.74 · 15 txns

  5. 5

    CAROLINE CHEBLI

    $12,311.01 · 8 txns

Summary Comparison

Metric BioMarin Pharmaceutical Inc. Catalyst OrthoScience
Total Payments $11.9M $11.8M
% of Industry Total 0.1% 0.1%
Transaction Count 4,140 448
Avg per Transaction $2.9K $26.4K
Recipient Count 2,932 424
Avg per Recipient $4.0K $27.9K
Payment Type Count 7 4
Top Payment Type Consulting Fee Royalty or License

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.